| Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia M Mesulam, A Wicklund, N Johnson, E Rogalski, GC Léger, A Rademaker, ... Annals of Neurology: Official Journal of the American Neurological …, 2008 | 473 | 2008 |
| Dopa decarboxylase activity of the living human brain. A Gjedde, J Reith, S Dyve, G Leger, M Guttman, M Diksic, A Evans, ... Proceedings of the National Academy of Sciences 88 (7), 2721-2725, 1991 | 189 | 1991 |
| 6-[18F]fluoro-l-DOPA Metabolism in Living Human Brain: A Comparison of Six Analytical Methods H Hoshi, H Kuwabara, G Léger, P Cumming, M Guttman, A Gjedde Journal of Cerebral Blood Flow & Metabolism 13 (1), 57-69, 1993 | 113 | 1993 |
| Human Striatal l-DOPA Decarboxylase Activity Estimated in vivo Using 6-[18F]fluoro-DOPA and Positron Emission Tomography: Error Analysis and Application to … H Kuwabara, P Cumming, J Reith, G Leger, M Diksic, AC Evans, ... Journal of Cerebral Blood Flow & Metabolism 13 (1), 43-56, 1993 | 113 | 1993 |
| Pharmacological treatment of Alzheimer disease F Massoud, GC Léger The Canadian Journal of Psychiatry 56 (10), 579-588, 2011 | 111 | 2011 |
| Pharmacokinetics of Plasma 6-[18F]Fluoro-l-3,4-Dihydroxyphenylalanine ([18F]FDOPA) in Humans P Cumming, GC Léger, H Kuwabara, A Gjedde Journal of Cerebral Blood Flow & Metabolism 13 (4), 668-675, 1993 | 83 | 1993 |
| Striatal L‐dopa decarboxylase activity in Parkinson's disease in vivo: implications for the regulation of dopamine synthesis A Gjedde, GC Léger, P Cumming, Y Yasuhara, AC Evans, M Guttman, ... Journal of neurochemistry 61 (4), 1538-1541, 1993 | 78 | 1993 |
| Regional striatal DOPA transport and decarboxylase activity in Parkinson's disease. H Kuwabara, P Cumming, Y Yasuhara, GC Léger, M Guttman, M Diksic, ... Journal of nuclear medicine: official publication, Society of Nuclear …, 1995 | 55 | 1995 |
| Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa M Guttman, G Leger, A Reches, A Evans, H Kuwabara, JM Cedarbaum, ... Movement disorders: official journal of the Movement Disorder Society 8 (3 …, 1993 | 50 | 1993 |
| Correction for partial volume effects in PET using MRI-based 3-D simulations of individual human brain metabolism OG Rousset, Y Ma, GC Leger, AH Gjedde, AC Evans Annals of Nuclear Medicine 7 (SUPPL. 1), S31-S32, 1993 | 47 | 1993 |
| 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain M Guttman, G Léger, JM Cedarbaum, A Reches, W Woodward, A Evans, ... Annals of Neurology: Official Journal of the American Neurological …, 1992 | 47 | 1992 |
| Reduction of circulating 3-O-methyldopa by inhibition of catechol-O-methyltransferase with OR-611 and OR-462 in cynomolgus monkeys: implications for the treatment of Parkinson … JM Cedarbaum, G Leger, M Guttman Clinical neuropharmacology 14 (4), 330-342, 1991 | 45 | 1991 |
| Neuropsychiatric symptom profile differs based on pathology in patients with clinically diagnosed behavioral variant frontotemporal dementia GC Léger, SJ Banks Dementia and geriatric cognitive disorders 37 (1-2), 104-112, 2014 | 39 | 2014 |
| Toward a revision of criteria for the dementias K Rockwood, RW Bouchard, R Camicioli, G Léger Alzheimer's & Dementia 3 (4), 428-440, 2007 | 35 | 2007 |
| Structural and functional MRI differences in master sommeliers: a pilot study on expertise in the brain SJ Banks, KR Sreenivasan, DM Weintraub, D Baldock, M Noback, ... Frontiers in Human Neuroscience 10, 414, 2016 | 24 | 2016 |
| Relationship between the activities of daily living questionnaire and the montreal cognitive assessment J Durant, GC Leger, SJ Banks, JB Miller Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 4 (1), 43-46, 2016 | 20 | 2016 |
| Effect of catechol‐O‐methyltransferase inhibition on brain uptake of [18F]fluorodopa: Implications for compartmental modelling and clinical usefulness G Léger, A Gjedde, H Kuwabara, M Guttman, P Cumming Synapse 30 (4), 351-361, 1998 | 20 | 1998 |
| Randomized controlled trials in frontotemporal dementia: cognitive and behavioral outcomes JB Miller, SJ Banks, GC Léger, JL Cummings Translational neurodegeneration 3 (1), 1-9, 2014 | 19 | 2014 |
| Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys. JM Cedarbaum, G Léger, A Reches, M Guttman Clinical neuropharmacology 13 (6), 544-552, 1990 | 19 | 1990 |
| A review on primary progressive aphasia GC Léger, N Johnson Neuropsychiatric disease and treatment 3 (6), 745, 2007 | 14 | 2007 |
Mark GuttmanCentre for Movement DisordersBestätigte E-Mail-Adresse bei movementdisorders.ca
